{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"The trial uses 3+3 design to determine maximum tolerated dose (MTD).","groups":[{"description":"40 mg BKM120 will be administered orally daily for 45 days. Cisplatin: Starting Dose 30 mg/m2 (Dose Level 1) or 35 mg/m2 (Dose Level 2), given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43).\n\nRadiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks.\n\nBKM120: BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor. Cisplatin: Cisplatin is a chemotherapy drug Intensity-modulated radiotherapy (IMRT): IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells","id":"OG000","title":"Dose Level 1 and Dose Level 2"}],"paramType":"NUMBER","populationDescription":"\\*One additional patient enrolled in Dose Level 1 per physician discretion","reportingStatus":"POSTED","timeFrame":"While on treatment, up to 66 days","title":"Maximum Tolerated Dose of BKM120","type":"PRIMARY","unitOfMeasure":"mg"}